top of page

Swollen Ankles on Amlodipine: Why a Water Pill Fails

Aug 16
4 min read

Updated: 2 hours ago


The short answer


Amlodipine ankle swelling comes from widened small arteries delivering fluid into leg tissue, rather than your whole body retaining water, so a diuretic usually does not fix it. Across 25 randomized trials, adding an ACE inhibitor or ARB reduced swelling by 38 percent. Lowering the amlodipine dose is another option to discuss with the prescriber. These are medication-review options, not instructions to stop a blood-pressure drug on your own.


What we cover


  • Why amlodipine swells your ankles and not your hands

  • The change that cut swelling by 38 percent across 25 trials, and why ACE inhibitors beat ARBs at it (Makani 2011)

  • Why the enalapril label understates the reported cough ninefold, and three tells that point at the pill (Bangalore 2010)

  • Why the potassium warning belongs on your salt substitute rather than your fruit bowl (Xu 2024)

  • What a creatinine rise after starting one of these drugs means, and the two numbers that trigger a look rather than a stop (Bakris and Weir 2000)

  • Why combining an ACE inhibitor and an ARB worsened kidney outcomes in ONTARGET. Primary source

  • The three-drug combination that raised acute kidney injury by about a third, worst in the first 30 days (Lapi 2013)


Timestamps


00:00 Amlodipine ankle swelling explained

02:44 Why amlodipine causes swollen ankles

03:48 What reduced ankle swelling by 38%

05:04 Lowering the amlodipine dose

05:44 ACE inhibitor dry cough

08:53 When medication swelling is an emergency

09:17 Potassium, bananas, and salt substitutes

10:11 Creatinine rise after ACE inhibitors and ARBs

12:23 The 30% creatinine rule

13:37 Dizziness when standing up

15:05 Why ACE inhibitors and ARBs should not be combined

16:30 The triple whammy and kidney injury

18:39 How to handle blood pressure pill side effects

19:42 Make a medication and symptom list


References


  • Makani H, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124(2):128-35. https://doi.org/10.1016/j.amjmed.2010.08.007

    Across 25 randomized trials and 17,206 patients, adding a renin-angiotensin blocker lowered peripheral edema by 38 percent and withdrawal for edema by 62 percent, with ACE inhibitors ahead of ARBs on an indirect comparison the authors say needs head-to-head testing. Systematic review and meta-analysis of randomized trials.


  • Liang L, et al. Comparative peripheral edema for dihydropyridine calcium channel blockers: systematic review and network meta-analysis. J Clin Hypertens. 2022;24(5):536-554. https://doi.org/10.1111/jch.14436

    Across 71 studies and 56,283 patients, amlodipine plus an ACE inhibitor produced the least edema among combination regimens, a separate ranking from monotherapy. Network meta-analysis.


  • Bangalore S, Kumar S, Messerli FH. ACE inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med. 2010;123(11):1016-30. https://doi.org/10.1016/j.amjmed.2010.06.014

    Across 125 studies and 198,130 patients, 11.48 percent taking enalapril reported a cough against 1.3 percent in the label, a ninefold gap, though that is the raw rate on the drug rather than the share the drug caused. Systematic review.


  • Xu X, et al. Potassium-enriched salt substitutes: a review of recommendations in clinical management guidelines. Hypertension. 2024;81(3):400-414. https://doi.org/10.1161/HYPERTENSIONAHA.123.21343

    Reviewed 32 hypertension and 14 kidney guidelines, found the guidance incomplete and inconsistent, and proposed draft wording excluding advanced kidney disease, a potassium supplement, or a potassium-sparing diuretic, which is the authors' proposal rather than adopted guideline text. Narrative review of guidelines.


  • Bakris GL, Weir MR. ACE inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685-93. https://doi.org/10.1001/archinte.160.5.685

    Sets the two thresholds still used today, a creatinine rise above 30 percent within two months or a potassium of 5.6 mmol/L or higher, as the point to reassess rather than automatically stop. Narrative review.


  • Juraschek SP, et al. Orthostatic hypotension, cardiovascular outcomes, and adverse events: results from SPRINT. Hypertension. 2020;75(3):660-667. https://doi.org/10.1161/HYPERTENSIONAHA.119.14309

    Dizziness on standing without symptoms was not associated with injurious falls, fainting, electrolyte problems, or acute kidney failure, though symptomatic episodes did track with hospital visits for low blood pressure. Secondary analysis of a randomized trial.


  • Mann JFE, et al. Renal outcomes with telmisartan, ramipril, or both (ONTARGET). Lancet. 2008;372(9638):547-53. https://doi.org/10.1016/S0140-6736(08)61236-2

    In 25,620 patients over a median 56 months, an ACE inhibitor and an ARB together cut urine protein more than either alone yet worsened major kidney outcomes. Randomized trial.


  • Lapi F, et al. Concurrent use of diuretics, ACE inhibitors, and ARBs with NSAIDs and risk of acute kidney injury. BMJ. 2013;346:e8525. https://doi.org/10.1136/bmj.e8525

    Across 487,372 patients, all three together raised acute kidney injury by 31 percent and by 82 percent in the first 30 days, against a baseline near 7 events per 10,000 person-years, while any two of the three showed no increase here. Observational cohort.


  • Jones DW, et al. 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Circulation. 2025;152(11):e114-e218. https://doi.org/10.1161/CIR.0000000000001356

    Retires and replaces the 2017 guideline, keeping a target under 130 over 80 for most adults. Clinical guideline.


One study explained in plain language every week, with sources attached, plus the free metabolic health guide: https://guides.selfprinciple.org/metabolic


This content is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Sean Hashmi's own and do not represent his employer.


Never start, stop, or change the dose of any prescription medication without consulting your physician.

Comments


The weekly email

Kidney and metabolic health, one study at a time.

One clear email each week: the research explained in plain English, and a practical next step you can take.

Join 10,000+ readers.

bottom of page